Abstracts tagged "Scleroderma, Localized"

Abstract Number: 0371 • ACR Convergence 2024
This Is Caring: Enhancing Patient Education Materials for Individuals with Morphea Through Qualitative Inquiry
Jennifer Foster¹, Robin Higashi², Priya Sarlashkar¹ and Heidi Jacobe¹, ¹The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, ²2UT Southwestern Medical Center, Peter O’Donnell Jr School of Public Health, Dallas, TX
Background/Purpose: Patient education materials (PEMs) are essential for conveying disease and treatment information, empowering patients to actively participate in their care. However, PEMs for rare…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 1767 • ACR Convergence 2024
Endothelial Cell-Driven JAG/NOTCH Signaling in Localized Scleroderma Patients
Theresa Hutchins¹, Anwesha Sanyal¹, Deren Esencan¹ and Kathryn Torok², ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Localized scleroderma is a rare autoimmune disease primarily affecting the skin and underlying tissue. While its exact pathogenesis remains unclear, studies suggest links to…
Abstract Number: 1774 • ACR Convergence 2024
Metabolomics and Lipidomics in Juvenile Localized Scleroderma
Yuan Zhang¹, Angela Aquilani², Rebecca Nicolai³, Fabrizio De Benedetti⁴, Emiliano Marasco² and Cristina Maglio¹, ¹University of Gothenburg, Gothenburg, Sweden, ²Bambino Gesù Children’s Hospital, Immunology and Rheumatology Unit, Roma, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Juvenile localised scleroderma (jLS) is a rare rheumatic disease in children characterized by inflammation and fibrosis in the skin [1, 2]. The cause and…
Abstract Number: 2178 • ACR Convergence 2024
Evaluating the Non-Inferiority of Mycophenolate Mofetil Compared to Methotrexate in Treating Juvenile Localized Scleroderma
Elena DeRosas¹, Haley Havrilla² and Kathryn Torok³, ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ³Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Methotrexate (MTX) has historically been used as first-line therapy for juvenile localized scleroderma (jLS), but tolerability often limit compliance. Recent evidence from case series…
Abstract Number: 2194 • ACR Convergence 2024
Association of Reticular Dermis and Subcutis Inflammatory Infiltrate with Musculoskeletal Involvement in Pediatric Localized Scleroderma
Deren Esencan¹, Anwesha Sanyal¹, Haley Havrilla², Samantha Branton¹, Theresa Hutchins¹, Claudia Salgado³ and Kathryn Torok⁴, ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ³University of Miami Miller School of Medicine, Miami, FL, ⁴Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Localized scleroderma (morphea) is a rare autoimmune disorder characterized by inflammatory infiltrate and collagen deposition in the skin and connective tissue. While textbooks offer…
Abstract Number: 0639 • ACR Convergence 2023
Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes
Antonio Salas¹, Lisa Yanek² and Zsuzsanna McMahan³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine Department of Medicine, Baltimore, MD, ³Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: Gastrointestinal (GI) dysmotility affects most patients with systemic sclerosis (SSc), and the esophagus is the most commonly affected region. While most SSc patients are…
Abstract Number: 0332 • ACR Convergence 2023
Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Jeong Min Yu¹, John VanBuren², Angela Child², Jessica Alvey², Lisa Mandl³, Laura Pinheiro⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Ashima Makol¹⁶, Jerry Molitor¹⁷, Duncan Moore¹⁸, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah²¹, Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug²⁴, Virginia Steen²⁵, Elizabeth Volkmann²⁶ and Jessica Gordon¹, ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine College, New York, NY, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁷University of Minnesota, Minneapolis, MN, ¹⁸Northwestern Memorial Hospital, Chicago, IL, ¹⁹Northwestern University, Riverside, IL, ²⁰University of Pennsylvania, Philadelphia, PA, ²¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²²Duke University, Durham, NC, ²³Victoria Shanmugam, MD, Great Falls, VA, ²⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶University of California Los Angeles, Los Angeles, CA
Background/Purpose: Skin disease is a hallmark of systemic sclerosis (SSc). The modified Rodnan skin score (mRSS) is physician performed measurement that assesses the extent and…
Abstract Number: 054 • 2023 Pediatric Rheumatology Symposium
Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort
Leigh Stubbs, Ammar Hashemi, Raegan Hunt and Renata Maricevich, Baylor College of Medicine, Houston, TX
Background/Purpose: Craniofacial localized scleroderma (LS) can lead to disfigurement and severe extracutaneous manifestations (ECMs). There is an ongoing need to standardize multidisciplinary evaluation and care.…
Abstract Number: 106 • 2023 Pediatric Rheumatology Symposium
Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Leigh Stubbs¹, Andrew Ferry², Danielle Guffey¹, Christina Loccke³, Erin Moriarty Wade³, Pamela Pour³, Kaveh Ardalan⁴, Peter Chiraseveenuprapund⁵, Ingrid Ganske⁶, Daniel Glaser⁷, Gloria Higgins⁸, Nadia Luca⁹, Katharine Moore¹⁰, Vidya Sivaraman¹¹, Katie Stewart¹, Natalia Vasquez Canizares¹², Raegan Hunt¹, Renata Maricevich¹, Kathryn Torok¹³ and Suzanne Li¹⁴, ¹Baylor College of Medicine, Houston, TX, ²Oregon Health and Science University, Portland, OR, ³n/a, ⁴Duke University School of Medicine, Durham, NC, ⁵University of California - San Diego, San Diego, CA, ⁶Boston Children’s Hospital and Harvard Medical School, Boston, MA, ⁷Yale University School of Medicine, New Haven, CT, ⁸Nationwide Childrens Hospital/ The Ohio State University, Columbus, OH, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Colorado / Children's Hospital Colorado, Denver, CO, ¹¹Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ¹²Children's Hospital at Montefiore, New York, NY, ¹³University of Pittsburgh, Pittsburgh, PA, ¹⁴Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (LS) and systemic sclerosis (SSc) are rare rheumatic diseases often associated with severe morbidities. Delays in diagnosis are common, putting children…
Abstract Number: 1366 • ACR Convergence 2022
Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma
Suzanne Li¹, Xiaohu Li², Tara Lozy³ and Jiajun Chen⁴, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, ²Stevens Institute of Technology, Hoboken, NJ, ³Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, ⁴One Node Lab, League City, TX
Background/Purpose: Juvenile localized scleroderma (jLS) is an inflammatory and fibrosing disease that causes severe morbidity (e.g., hemiatrophy, arthropathy, seizures), with functional impairment found in >25%…
Abstract Number: 1368 • ACR Convergence 2022
How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey
Ivan Foeldvari¹, Nicola Helmus² and Suzanne Li³, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ³Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ
Background/Purpose: Pediatric scleroderma consists of two diseases, juvenile localized scleroderma (jLS) and juvenile systemic sclerosis (jSSc). While jLS and jSSc share some disease processes, there…
Abstract Number: 1382 • ACR Convergence 2022
Juvenile Eosinophilic Fasciitis: A Single-Center Cohort
Leigh Stubbs¹, Oluwaseun Ogunbona², Adekunle Adesina¹, Sara Anvari¹, Emily Beil¹, Jamie Lai¹, Andrea Ramirez¹, Vibha Szafron¹, Matthew Ditzler¹ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Houston Methodist Hospital, Houston, TX
Background/Purpose: Eosinophilic fasciitis (EF) is a rare fibrosing disease. Since described in 1975, less than 30 pediatric cases have been reported. EF presents with painful…
Abstract Number: 1518 • ACR Convergence 2022
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
Ashima Makol¹, Alicia Hinze², Rachel Giblon¹, Yasser Radwan³, Tina Gunderson⁴, David Liedl¹, Kenneth J. Warrington⁴, Cynthia Crowson⁵ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic/ Michigan State University, Lansing, MI, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Digital ischemic complications (DICs, including digital ulcers, digital pitting/scars, gangrene and/or amputation) can significantly impact hand function, disability and overall prognosis in SSc. We…
Abstract Number: 1542 • ACR Convergence 2022
Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
Shery Susan Philip¹, Ramya Janardana¹, Revanesh S Mirji¹, Chengappa Kavadichanda², Devender Bairwa³, Geetabali Sircar⁴, Parasar Ghosh⁵, Anupam Wakhlu⁶, Padmanabha Shenoy⁷, Sumithra Selvam⁸ and Vineeta Shobha¹, ¹St. John’s Medical College Hospital, Bangalore, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁴Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, ⁵Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁶Apollo Medics Super Speciality Hospitals, Lucknow, India, ⁷Centre for Arthritis and Rheumatism Excellence (CARE), Cochi, India, ⁸Division of Epidemiology and Biostatistics, St. John’s Research Institute, St. John's Medical College Hospital, Bangalore, India
Background/Purpose: Classification of systemic sclerosis (SSc) into subsets has been a challenge due to it's heterogeneity. This study attempts to identify SSc subsets based on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].